U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07426822) titled 'Rash & Diarrhea Prophylaxis With Capivasertib' on Feb. 09.
Brief Summary: This is a randomized, multicenter, phase II clinical trial evaluating prophylactic strategies to mitigate common toxicities associated with capivasertib in combination with fulvestrant in participants with hormone receptor-positive (HR+), HER2-negative advanced breast cancer who are eligible for this treatment regimen.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Metastatic HR+/HER2- Breast Cancer
Intervention:
DRUG: Capivasertib
400 mg orally, twice daily (BID), on 4-days-on/3-days-off schedule.
DRUG: Loperamide
2 mg orally onc...